Association Between Plasma Levels of ANGPTL3, 4, 8 and the Most Common Additional Cardiovascular Risk Factors in Patients with Hypertension

References

• McManus RJ, Mant J, Franssen M, et al. Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial. Lancet. 2018;391(10124):949–959. doi:10.1016/S0140-6736(18)30309-X
   PubMed Web of Science ®Google Scholar
• Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75:1334–1357.
   PubMed Web of Science ®Google Scholar
• Santulli G. Angiopoietin-like proteins: a comprehensive look. Front Endocrinol. 2014;5:4.
   PubMed Web of Science ®Google Scholar
• Endo M. The roles of angptl families in cancer progression. J UOEH. 2019;41:317–325.
   PubMedGoogle Scholar
• Abu-Farha M, Ghosh A, Al-Khairi I, Madiraju S, Abubaker J, Prentki M. The multi-faces of Angptl8 in health and disease: novel functions beyond lipoprotein lipase modulation. Prog Lipid Res. 2020;80:101067.
   PubMed Web of Science ®Google Scholar
• Sylvers-Davie KL, Davies B. Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8. Am J Physiol-Endoc M. 2021;321:E493–E508.
   PubMed Web of Science ®Google Scholar
• Yang J, Song QY, Niu SX, et al. Emerging roles of angiopoietin-like proteins in inflammation: mechanisms and potential as pharmacological targets. J Cell Physiol. 2022;237:98–117.
   PubMed Web of Science ®Google Scholar
• Kersten S. New insights into angiopoietin-like proteins in lipid metabolism and cardiovascular disease risk. Curr Opin Lipidol. 2019;30:205–211.
   PubMed Web of Science ®Google Scholar
• Jin N, Matter WF, Michael LF, et al. The Angiopoietin-Like Protein 3 and 8 Complex Interacts with Lipoprotein Lipase and Induces LPL Cleavage. Acs Chem Biol. 2021;16:457–462.
   PubMed Web of Science ®Google Scholar
• Abu-Farha M, Al-Khairi I, Cherian P, et al. Increased ANGPTL3, 4 and ANGPTL8/betatrophin expression levels in obesity and T2D. Lipids Health Dis. 2016;15(1):181. doi:10.1186/s12944-016-0337-x
   PubMedGoogle Scholar
• Schinzari F, Vizioli G, Campia U, Tesauro M, Cardillo C. Variable Changes of Circulating ANGPTL3 and ANGPTL4 in Different Obese Phenotypes: relationship with Vasodilator Dysfunction. Biomedicines. 2021;9(8):1037. doi:10.3390/biomedicines9081037
   PubMed Web of Science ®Google Scholar
• Barja-Fernandez S, Moreno-Navarrete JM, Folgueira C, et al. Plasma ANGPTL-4 is Associated with Obesity and Glucose Tolerance: cross-Sectional and Longitudinal Findings. Mol Nutr Food Res. 2018;62:e1800060.
   PubMed Web of Science ®Google Scholar
• Barchetta I, Chiappetta C, Ceccarelli V, et al. Angiopoietin-Like Protein 4 Overexpression in Visceral Adipose Tissue from Obese Subjects with Impaired Glucose Metabolism and Relationship with Lipoprotein Lipase. Int J Mol Sci. 2020;21.
   PubMed Web of Science ®Google Scholar
• Abu-Farha M, Abubaker J, Al-Khairi I, et al. Higher plasma betatrophin/ANGPTL8 level in Type 2 Diabetes subjects does not correlate with blood glucose or insulin resistance. Sci Rep-UK. 2015;5:10949.
   PubMed Web of Science ®Google Scholar
• Abu-Farha M, Sriraman D, Cherian P, et al. Circulating ANGPTL8/Betatrophin Is Increased in Obesity and Reduced after Exercise Training. PLoS One. 2016;11:e147367.
   PubMed Web of Science ®Google Scholar
• Fu Z, Berhane F, Fite A, Seyoum B, Abou-Samra AB, Zhang R. Elevated circulating lipasin/betatrophin in human type 2 diabetes and obesity. Sci Rep-UK. 2014;4:5013.
   PubMed Web of Science ®Google Scholar
• Morinaga J, Zhao J, Endo M, et al. Association of circulating ANGPTL 3, 4, and 8 levels with medical status in a population undergoing routine medical checkups: a cross-sectional study. PLoS One. 2018;13:e193731.
   PubMed Web of Science ®Google Scholar
• Arab SZ, Nourbakhsh M, Alaee M, et al. Angiopoietin-Like Proteins 2 and 3 in Children and Adolescents with Obesity and Their Relationship with Hypertension and Metabolic Syndrome. Int J Hypertens. 2021;2021:6748515.
   PubMed Web of Science ®Google Scholar
• Abu-Farha M, Cherian P, Qaddoumi MG, et al. Increased plasma and adipose tissue levels of ANGPTL8/Betatrophin and ANGPTL4 in people with hypertension. Lipids Health Dis. 2018;17:35.
   PubMed Web of Science ®Google Scholar
• Hussain A, Sun C, Selvin E, et al. Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: atherosclerosis Risk in Communities (ARIC) study. Eur J Prev Cardiol. 2022;29:e53–e64.
   PubMed Web of Science ®Google Scholar
• Aghasizadeh M, Zare-Feyzabadi R, Kazemi T, et al. A haplotype of the ANGPTL3 gene is associated with CVD risk, diabetes mellitus, hypertension, obesity, metabolic syndrome, and dyslipidemia. Gene. 2021;782:145525.
   PubMed Web of Science ®Google Scholar
• Chen MC, Hsu BG, Lee CJ, Wang JH. High-Serum Angiopoietin-Like Protein 3 Levels Associated with Cardiovascular Outcome in Patients with Coronary Artery Disease. Int J Hypertens. 2020;2020:2980954.
   PubMed Web of Science ®Google Scholar
• Muendlein A, Saely CH, Leiherer A, et al. Angiopoietin-like protein 4 significantly predicts future cardiovascular events in coronary patients. Atherosclerosis. 2014;237:632–638.
   PubMed Web of Science ®Google Scholar
• Leiherer A, Ebner J, Muendlein A, et al. High betatrophin in coronary patients protects from cardiovascular events. Atherosclerosis. 2020;293:62–68.
   PubMed Web of Science ®Google Scholar
• El HS, Mahmoud YZ, Saedii AA, et al. Angiopoietin-like proteins 3, 4 and 8 are linked to cardiovascular function in naive sub-clinical and overt hypothyroid patients receiving levothyroxine therapy. Endocr Connect. 2021;10:1570–1583.
   PubMed Web of Science ®Google Scholar
• Morelli MB, Chavez C, Santulli G. Angiopoietin-like proteins as therapeutic targets for cardiovascular disease: focus on lipid disorders. Expert Opin Ther Tar. 2020;24:79–88.
   PubMed Web of Science ®Google Scholar
• Ulijaszek SJ. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. Who Tech Rep Ser. 2000;894:1–253.
   Web of Science ®Google Scholar
• de Boer IH, Katz R, Fried LF, et al. Obesity and change in estimated GFR among older adults. Am J Kidney Dis. 2009;54:1043–1051.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Goldberg IJ. Broadening the Scope of Dyslipidemia Therapy by Targeting APOC3 (Apolipoprotein C3) and ANGPTL3 (Angiopoietin-Like Protein 3). Arterioscl Throm Vas. 2023;43:388–398.
   Google Scholar
• Sahebkar A, Chew GT, Watts GF. Recent advances in pharmacotherapy for hypertriglyceridemia. Prog Lipid Res. 2014;56:47–66.
   PubMed Web of Science ®Google Scholar
• Graham MJ, Lee RG, Brandt TA, et al. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. New Engl J Med. 2017;377:222–232.
   PubMed Web of Science ®Google Scholar
• Bloch MJ, Viera AJ. Should patients with obesity and hypertension be treated differently from those who are not obese? Curr Hypertens Rep. 2014;16:418.
   PubMed Web of Science ®Google Scholar
• Engeli S, Jordan J. Novel metabolic drugs and blood pressure: implications for the treatment of obese hypertensive patients? Curr Hypertens Rep. 2013;15:470–474.
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Gonzalez-Villalpando C, Meigs JB, Ferrannini E. Hypertension and Diabetes Mellitus: coprediction and Time Trajectories. Hypertension. 2018;71:422–428.
   PubMed Web of Science ®Google Scholar
• Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: clinical Insights and Vascular Mechanisms. Can J Cardiol. 2018;34:575–584.
   PubMed Web of Science ®Google Scholar
• Wilson FH, Hariri A, Farhi A, et al. A cluster of metabolic defects caused by mutation in a mitochondrial tRNA. Science. 2004;306:1190–1194.
   PubMed Web of Science ®Google Scholar
• Rabin JS, Schultz AP, Hedden T, et al. Interactive Associations of Vascular Risk and beta-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals: findings From the Harvard Aging Brain Study. JAMA Neurol. 2018;75:1124–1131.
   PubMed Web of Science ®Google Scholar
• Peng J, Vongpatanasin W, Sacharidou A, et al. Supplementation With the Sialic Acid Precursor N-Acetyl-D-Mannosamine Breaks the Link Between Obesity and Hypertension. Circulation. 2019;140:2005–2018.
   PubMed Web of Science ®Google Scholar
• Cinkajzlova A, Mraz M, Lacinova Z, et al. Angiopoietin-like protein 3 and 4 in obesity, type 2 diabetes mellitus, and malnutrition: the effect of weight reduction and realimentation. Nutr Diabetes. 2018;8:21.
   PubMed Web of Science ®Google Scholar
• Yin Y, Ding X, Peng L, et al. Increased Serum ANGPTL8 Concentrations in Patients with Prediabetes and Type 2 Diabetes. J Diabetes Res. 2017;2017:8293207.
   PubMed Web of Science ®Google Scholar
• Chen X, Lu P, He W, et al. Circulating betatrophin levels are increased in patients with type 2 diabetes and associated with insulin resistance. J Clin Endocr Metab. 2015;100:E96–E100.
   PubMed Web of Science ®Google Scholar
• Xie X, Gao T, Yang M, et al. Associations of betatrophin levels with irisin in Chinese women with normal glucose tolerance. Diabetol Metab Syndr. 2015;7:26.
   PubMed Web of Science ®Google Scholar
• Hu H, Sun W, Yu S, et al. Increased circulating levels of betatrophin in newly diagnosed type 2 diabetic patients. Diabetes Care. 2014;37:2718–2722.
   PubMed Web of Science ®Google Scholar
• Ebert T, Kralisch S, Hoffmann A, et al. Circulating angiopoietin-like protein 8 is independently associated with fasting plasma glucose and type 2 diabetes mellitus. J Clin Endocr Metab. 2014;99:E2510–E2517.
   PubMed Web of Science ®Google Scholar
• Gomez-Ambrosi J, Pascual E, Catalan V, et al. Circulating betatrophin concentrations are decreased in human obesity and type 2 diabetes. J Clin Endocr Metab. 2014;99:E2004–E2009.
   PubMed Web of Science ®Google Scholar
• Ejarque M, Borlaug M, Vilarrasa N, et al. Angiopoietin-like protein 8/betatrophin as a new determinant of type 2 diabetes remission after bariatric surgery. Transl Res. 2017;184:35–44.
   PubMed Web of Science ®Google Scholar
• Fenzl A, Itariu BK, Kosi L, et al. Circulating betatrophin correlates with atherogenic lipid profiles but not with glucose and insulin levels in insulin-resistant individuals. Diabetologia. 2014;57:1204–1208.
   PubMed Web of Science ®Google Scholar
• Guo K, Lu J, Yu H, et al. Serum betatrophin concentrations are significantly increased in overweight but not in obese or type 2 diabetic individuals. Obesity. 2015;23:793–797.
   PubMed Web of Science ®Google Scholar
• Gao X, Suo Y, Zhang M, et al. Angiopoietin-like protein 3 markedly enhanced in the hyperlipidemia related proteinuria. Lipids Health Dis. 2019;18:116.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for Homozygous Familial Hypercholesterolemia. New Engl J Med. 2020;383:711–720.
   PubMed Web of Science ®Google Scholar
• Wang X, Musunuru K. Angiopoietin-Like 3: from Discovery to Therapeutic Gene Editing. Jacc-Basic Transl Sc. 2019;4:755–762.
   PubMedGoogle Scholar
• Fukami H, Morinaga J, Nakagami H, et al. Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia. Cell Rep Med. 2021;2:100446.
   PubMedGoogle Scholar